About
Technology
Issues
FAQ
Links
Official Page
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.